Welcome back to another edition of Endpoints Weekly! We’re doing a little bit of celebrating here at Endpoints, as we took home three Neal Awards,

The FDA dropped a surprise Friday announcement that three more National Priority Vouchers would be given to a trio of psychedelics companies.

The FDA said Friday it has issued new fast-track vouchers to three psychedelic companies, and its selections have come as a “surprise” to Wall Street.

Avalyn Pharma plots $182M IPO: The biotech, which is making inhaled versions of approved pulmonary fibrosis medicines, anticipates about $182 million in net proceeds if

Novartis has withdrawn its EU application for radioligand therapy Pluvicto’s expansion into earlier prostate cancer treatment, despite US and UK approval for the same indication.